handshake-1
miodrag ignjatovic / iStockphoto.com
18 July 2018Americas

AbbVie and Mylan agree Humira licensing deal

US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
8 November 2018   Biotech company Momenta has obtained the rights to use AbbVie’s Humira IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.
Generics
29 April 2021   Mylan can deduct legal fees from defending itself against patent infringement suits as business expenses, according to the US Tax Court.
Big Pharma
11 May 2021   MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.

More on this story

Americas
8 November 2018   Biotech company Momenta has obtained the rights to use AbbVie’s Humira IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.
Generics
29 April 2021   Mylan can deduct legal fees from defending itself against patent infringement suits as business expenses, according to the US Tax Court.
Big Pharma
11 May 2021   MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.

More on this story

Americas
8 November 2018   Biotech company Momenta has obtained the rights to use AbbVie’s Humira IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.
Generics
29 April 2021   Mylan can deduct legal fees from defending itself against patent infringement suits as business expenses, according to the US Tax Court.
Big Pharma
11 May 2021   MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.